STOCK TITAN
  1. Home
  2. News
  3. CLABF

Core One Labs Inc - CLABF STOCK NEWS

Welcome to our dedicated news page for Core One Labs (Ticker: CLABF), a resource for investors and traders seeking the latest updates and insights on Core One Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Core One Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Core One Labs's position in the market.

News
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Rhea-AI Summary
Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) is pleased to announce the signing of an Initial Agreement with Cube Psytech Corp. marking a significant step towards exploring the potential sale of biosynthetically produced psilocybin or the licensing of its proprietary method for biosynthetic psilocybin production technology. This Agreement could set the stage for Core One products to enter the international market. Cube Psytech is a Canadian bio-pharmaceutical and biotechnology company focused on psilocybin and psilocin research and development programs designed to create innovative drugs and protocols for clinical trials and patient prescribed uses globally. Core One, leveraging its wholly-owned subsidiaries, has successfully developed a proprietary method for the manufacturing of biosynthetic psilocybin and synthetic psilocin. The successful conclusion of any sale or licensing transaction with Cube Psytech remains contingent on several conditions, including the satisfactory completion of due diligence by each party, the negotiation and execution of definitive documentation, and compliance with applicable laws in Core One's and Cube Psytech's operating jurisdictions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Rhea-AI Summary
Core One Labs Inc. (COOL) has announced promising results from its first round of Stage 2 animal model studies in collaboration with Universitat de Barcelona for its subsidiary, Akome Biotechnologies Inc. The studies demonstrate potential for innovative treatment alternatives for Alzheimer's and Parkinson's, marking a significant step forward in the field of neuroscience and psychedelics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Rhea-AI Summary
Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU) Announces Positive Results from Round 2 of Stage 1 Animal Model Studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Rhea-AI Summary
Core One's wholly-owned subsidiary, Awakened Biosciences, has filed a patent application for isolating and purifying psilocybin from mushroom biomass. This breakthrough allows Core One to enter the mushroom cultivation market and offer cutting-edge solutions for extracting active ingredients. It positions the company to capitalize on the emerging medical and recreational psychedelics market, similar to the cannabis industry. The patent complements Core One's existing production methods and provides a safe and consistent supply of psilocybin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
-
News
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
News
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Core One in Talks with Multiple Companies to Supply Psilocybin
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
News
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock CLABF logo
Core One Labs Inc

OTC:CLABF

CLABF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CLABF Stock Data

7.44M
46.28M
0.3%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver